Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Carcinoma, Renal Cell × Tablets × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 3 Vomiting 1 Prostatic Neoplasms 1 Parathyroid Neoplasms 1 Neoplasms 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Acute 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia, Hairy Cell 1 Leukemia, B-Cell 1 Hyperparathyroidism, Primary 1 Hot Flashes 1 Erectile Dysfunction 1 Diabetes Mellitus 1 Carcinoma, Renal Cell 1

Interventions

Sunitinib 17 Nivolumab 12 pembrolizumab 10 Sorafenib 10 cabozantinib 9 Interferon-alpha 9 pazopanib 8 Everolimus 8 Bevacizumab 7 belzutifan 6 aldesleukin 6 Ipilimumab 6 lenvatinib 5 Magnetic Resonance Spectroscopy 5 Axitinib 5 atezolizumab 4 temsirolimus 3 Radiosurgery 3 Nephrectomy 3 Interferon alpha-2 3 tivozanib 2 durvalumab 2 avelumab 2 Specimen Handling 2 Saline Solution 2 Interleukin-2 2 G250 monoclonal antibody 2 Fluorouracil 2 Chemotherapy, Adjuvant 2 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01865747 2021-04-27

METEOR

Exelixis

Phase 3 Completed

658 enrolled 15 charts

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡